Our previous in vitro and in vivo studies using colon cancer cells with a targeted down-regulation of SelenoF or using a systemic Selenof-KO mouse model, saw a reversal of the colon cancer phenotype [18,26] and a decreased number of chemically induced pre-neoplastic lesions [26], respectively. This evidence concerns the gene SELENOF and colonic neoplasm.